Fetal Medicine Foundation tag:www.fetalmedicine.com,2008-10-30:/fmf//1 2012-01-10T14:46:40Z Movable Type Pro 4.21-en ברוכים הבאים קרן רפואה עוברית tag:www.fetalmedicine.com,2012:/fmf//1.246 2012-01-10T14:13:57Z 2012-01-10T14:46:40Z קרן לרפואה עוברית היא צדקה רשום שמטרתו לשפר את הבריאות של נשים בהריון ותינוקות שלהם דרך מחקר והכשרה בתחום הרפואה העובר. קרן, עם תמיכה של קבוצה בינלאומית של מומחים, הציגה תוכנית חינוכית הן לאנשי מקצוע בריאות הורים סדרה של תעודות... FMF קרן לרפואה עוברית היא צדקה רשום שמטרתו לשפר את הבריאות של נשים בהריון ותינוקות שלהם דרך מחקר והכשרה בתחום הרפואה העובר. קרן, עם תמיכה של קבוצה בינלאומית של מומחים, הציגה תוכנית חינוכית הן לאנשי מקצוע בריאות הורים סדרה של תעודות יכולת בהיבטים שונים של רפואה עוברית.
ב -15 השנים האחרונות, הקרן תמכה מחקר והכשרה בתחומים הבאים באמצעות מענקים בסך של יותר מ 11,000,000£
  • אבחון מוקדם של מומים בעובר
  • הקרנת עבור פגם כרומוזומלי
  • ניתוח עוברי תוך רחמי
  • גורם ומניעת להפלות וללידת עובר מת
  • חיזוי ומניעת לידה מוקדמת
  • רעלת הריון והגבלת הגידול העוברי
  • בעיות של הריונות מרובים
  • פיתוח שיטות בטוחות יותר לאבחון טרום לידתי

אם אתה איש מקצוע בריאות אתה רוצה ללכת לדף FMF משלך עליך להכנס להלן:



]]> ברשת החינוך

 

הקורסים הם ללא תשלום והם מתאימים גם אנשי מקצוע בתחום הבריאות והחולים

בשבועות 11-13 סריקה
הערכה צוואר הרחם
מעקב ההיריון
עוברית אקו

]]> The Kipriotis hotels: List and information tag:www.fetalmedicine.com,2011:/fmf//1.245 2011-12-20T03:13:04Z 2012-01-31T18:10:38Z FMF These hotels have agreed to provide special rates for the congress delegates. In all cases the following cancellation and extra person policies apply.

 

cancellation.jpg

The congress will be held in the Kos International Convention Centre is situated adjacent to Kipriotis Village

 

Kipriotis Village - Congress venue

Classification: Superior 4 stars
Location: Psalidi, 85 300, Kos
Tel: +30 22420 55300, Fax: +30 22420 23590, Website click here

Rates: Bed and breakfast, single €100, double €120

photos_kipriotis_village.jpg

This hotel is located right at the seashore, only 3 km from Kos town, at a breathtaking setting in the heart of palm tree fields and vast gardens overlooking the sea. It offers a multiple choice of restaurants, bars, coffee shops, a wide range of excellent sport and leisure facilities and also a health studio and spa. Daily animation entertainment programs are also provided for children, along with a lovely children's playground and a children's pool.

 

Kipriotis Maris

Classification: 5 stars
Location: Psalidi, 85 300, Kos
Tel: +30 22420 57150, Fax: +30 22420 21936, Website click here

Rates: Bed and breakfast, single €100, double €120

photos_kipriotis_maris.jpg

Situated across the street from the congress venue, up on the hill. A luxurious property, decorated in a modern fashion, offering a great view to the sea, the surrounding islands and the Turkish coast. All rooms have a balcony or terrace, build in bungalow complexes all around the pool and garden area. You may use the facilities of the neighboring hotel complex, such as the beautiful "Playland" for children

 

Kipriotis Panorama Hotel & Suites

Classification: 5 stars
Location: Psalidi, 85 300, Kos
Tel: +30 22420 57000, Fax: +30 22420 22974, Website click here

Rates: Bed and breakfast, single €120, double €140

photos_kipriotis_panorama.jpg

Located on a hillside and offers an outstanding view over the Aegean Sea, the surrounding islands and the Turkish coast. This is a modern and luxurious property that blends into lovely mountain scenery. Among the others hotel's facilities, guests can find a health studio & spa and a children's playground.

 

Kipriotis Panorama Aqualand

Classification: 4 stars hotel
Location: Psalidi, 85 300, Kos
Tel: +30 22420 57100, Fax: +30 22420 29960, Website click here

Rates: Bed and breakfast, double €90, triple €121.50

photos_kipriotis_aqualand.jpg

Situated right next to the Panorama Hotel & Suites in a quiet hillside location with a majestic view over the Aegean Sea, the surrounding islands and the Turkish coast. Panorama Aqualand is a luxurious and relaxing property for the whole family, including 2 main pools, one with waterslides, and a children's pool. You may choose this property if you want to take advantage of the special apartment space which is ideal for more than 2 persons.

 

Kipriotis Hippocrates Hotel

Classification: 4 stars
Location: Psalidi, 85 300, Kos
Tel: +30 22420 24401, Fax: +30-22420-24410, Website click here

**Rates: Bed and breakfast, single €90, double €105

photos_kipriotis_hippocrates.jpg

Located in quiet surroundings, with an excellent sea view and a beautiful spacious garden. It is only 200 m away from the congress venue. Leisure and sport facilities include table tennis, beach volleyball, 2 tennis hardcourts, fitness room, darts, archery, billiards. Directly in front of the hotel there is a bicycle road to all directions and the public bus station with regular daily schedule to Kos town. This hotel is the ideal accommodation if you seek for a casual and family like atmosphere.

 

Return to top of page

]]> Book now!

 

]]> 2011 tag:www.fetalmedicine.com,2011:/fmf//1.241 2011-01-24T13:15:55Z 2011-12-27T16:58:24Z Akolekar R, Bower S, Flack N, Bilardo CM, Nicolaides KH. Prediction of miscarriage and stillbirth at 11-13 weeks and the contribution of chorionic villus sampling. Prenat Diagn 2011;31:38-45 pdf Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH.... FMF
  • Akolekar R, Bower S, Flack N, Bilardo CM, Nicolaides KH.
    Prediction of miscarriage and stillbirth at 11-13 weeks and the contribution of chorionic villus sampling.
    Prenat Diagn 2011;31:38-45 pdf
  • Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH.
    Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks.
    Prenat Diagn 2011;31:66-74 pdf erratum
  • Akolekar R, Cruz JJ, Penco JM, Zhou Y, Nicolaides KH.
    Maternal plasma plasminogen activator inhibitor-2 at 11 to 13 Weeks of gestation in hypertensive disorders of pregnancy.
    Hypertens Pregnancy 2011;30:194-202
  • Akolekar R, Finning K, Kuppusamy R, Daniels G, Nicolaides KH.
    Fetal RHD Genotyping in Maternal Plasma at 11-13 Weeks of Gestation.
    Fetal Diagn Ther 2011;29:301-6 pdf
  • Ashoor G, Maiz N, Cuckle H, Jawdat F, Nicolaides KH.
    Maternal thyroid function at 11-13 weeks of gestation in fetal trisomies 21 and 18.
    Prenat Diagn 2011;31:33-7 pdf
  • Ashoor G, Maiz N, Rotas M, Jawdat F, Nicolaides KH.
    Maternal thyroid function at 11-13 weeks of gestation and spontaneous preterm delivery.
    Obstet Gynecol 2011;117:293-8
  • Beta J, Akolekar R, Ventura W, Syngelaki A, Nicolaides KH.
    Prediction of spontaneous preterm delivery from maternal factors, obstetric history and placental perfusion and function at 11-13 weeks.
    Prenat Diagn 2011;31:75-83 pdf
  • Beta J, Szekeres-Bartho J, Skyfta E, Akolekar R, Nicolaides KH.
    Maternal serum progesterone-induced blocking factor at 11-13 weeks gestation in spontaneous early preterm delivery.
    Fetal Diagn Ther 2011;29:197-200 pdf
  • Beta J, Bredaki FE, Calvo JR, Akolekar R, Nicolaides KH.
    Maternal serum a-fetoprotein at 11-13 weeks' gestation in spontaneous early preterm delivery.
    Fetal Diagn Ther 2011;30:88-93 pdf
  • Bombard AT, Akolekar R, Farkas DH, Vanagtmael AL, Aquino F, Oeth P, Nicolaides KH.
    Fetal RHD genotype detection from circulating cell-free fetal DNA in maternal plasma in non-sensitized RhD negative women.
    Prenat Diagn 201;31:802-8 pdf
  • Bredaki FE, Wright D, Matos P, Syngelaki A, Nicolaides KH.
    First-Trimester Screening for Trisomy 21 Using Alpha-Fetoprotein.
    Fetal Diagn Ther 2011;30:215-8 pdf
  • NewBredaki FE, Wright D, Akolekar R, Cruz G, Nicolaides KH.
    Maternal serum alpha-fetoprotein in normal pregnancy at 11-13 weeks' gestation.
    Fetal Diagn Ther 2011;30:274-9 pdf
  • Carbone IF, Cruz JJ, Sarquis R, Akolekar R, Nicolaides KH.
    Assisted conception and placental perfusion assessed by uterine artery Doppler at 11-13 weeks' gestation.
    Hum Reprod 2011;26:1659-64
  • Cetin I, Huppertz B, Burton G, Cuckle H, Gonen R, Lapaire O, Mandia L, Nicolaides K, Redman C, Soothill P, Spencer K, Thilaganathan B, Williams D, Meiri H.
    Pregenesys pre-eclampsia markers consensus meeting: What do we require from markers, risk assessment and model systems to tailor preventive strategies?
    Placenta 2011;32:S4-16
  • Chaveeva P, Carbone IF, Syngelaki A, Akolekar R, Nicolaides KH.
    Contribution of Method of Conception on Pregnancy Outcome after the 11-13 Weeks Scan.
    Fetal Diagn Ther 2011;30:9-22 pdf
  • Chelemen T, Syngelaki A, Maiz N, Allan L, Nicolaides KH.
    Contribution of ductus venosus doppler in first-trimester screening for major cardiac defects.
    Fetal Diagn Ther 2011;29:127-34 pdf
  • Chen M, Wang HF, Leung TY, Sahota DS, Borenstein M, Nicolaides K, Lao TT, Lau TK.
    Frontomaxillary facial angle at 11 + 0 to 13 + 6 weeks in Chinese population.
    J Matern Fetal Neonatal Med 2011;24:498-501
  • Chen EZ, Chiu RW, Sun H, Akolekar R, Chan KC, Leung TY, Jiang P, Zheng YW, Lun FM, Chan LY, Jin Y, Go AT, Lau ET, To WW, Leung WC, Tang RY, Au-Yeung SK, Lam H, Kung YY, Zhang X, van Vugt JM, Minekawa R, Tang MH, Wang J, Oudejans CB, Lau TK, Nicolaides KH, Lo YM.
    Noninvasive prenatal diagnosis of fetal trisomy 18 and trisomy 13 by maternal plasma DNA sequencing.
    PLoS One 2011;6:21791 pdf
  • Chiu RW, Akolekar R, Zheng YW, Leung TY, Sun H, Chan KC, Lun FM, Go AT, Lau ET, To WW, Leung WC, Tang RY, Au-Yeung SK, Lam H, Kung YY, Zhang X, van Vugt JM, Minekawa R, Tang MH, Wang J, Oudejans CB, Lau TK, Nicolaides KH, Lo YM.
    Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study.
    BMJ 2011;342:c7401 pdf
  • Deprest J, Nicolaides K, Done' E, Lewi P, Barki G, Largen E, Dekoninck P, Sandaite I, Ville Y, Benachi A, Jani J, Amat-Roldan I, Gratacos E.
    Technical aspects of fetal endoscopic tracheal occlusion for congenital diaphragmatic hernia.
    J Pediatr Surg 2011;46:22-32
  • Deprest JA, Nicolaides K, Gratacos E.
    Fetal surgery for congenital diaphragmatic hernia is back from never gone.
    Fetal Diagn Ther 2011;29:6-17 pdf
  • Derwig IE, Akolekar R, Zelaya FO, Gowland PA, Barker GJ, Nicolaides KH.
    Association of placental volume measured by MRI and birth weight percentile.
    J Magn Reson Imaging 2011;34:1125-30
  • Ferreira AF, Rezende JC, Vaikousi E, Akolekar R, Nicolaides KH.
    Maternal serum visfatin at 11-13 Weeks of gestation in gestational diabetes mellitus.
    Clin Chem 2011;57:609-13
  • Giambona A, Makrydimas G, Leto F, Damiani G, Jakil MC, Picciotto F, Renda D, Fiorino R, Renda MC, Schillaci G, Gueli-Alletti D, Nicolaides KH, Maggio A.
    Feasibility of DNA diagnosis of haemoglobinopathies on coelocentesis.
    Br J Haematol 2011;153,268-272
  • Gielchinsky Y, Zvanca M, Minekawa R, Persico N, Nicolaides KH.
    Liver volume in trisomy 21 and euploid fetuses at 11 to 13 weeks.
    Prenat Diagn 2011;31:28-32 pdf
  • Gielchinsky Y, Zvanca M, Akolekar R, Calvo JR, Nicolaides KH.
    Adrenal gland length in euploid and trisomy 18 fetuses at 11-13 weeks.
    Prenat Diagn 2011;31:773-7 pdf
  • Greco E, Lange A, Ushakov F, Calvo JR, Nicolaides KH.
    Prediction of spontaneous preterm delivery from endocervical length at 11 to 13 weeks.
    Prenat Diagn 2011;31:84-9 pdf
  • Jani J, Valencia C, Cannie M, Vuckovic A, Sellars M, Nicolaides KH.
    Tracheal diameter at birth in severe congenital diaphragmatic hernia treated by fetal endoscopic tracheal occlusion.
    Prenat Diagn 2011;31:699-704 pdf
  • Karagiannis G, Akolekar R, Sarquis R, Wright D, Nicolaides KH."
    Prediction of small-for-gestation neonates from biophysical and biochemical markers at 11-13 weeks.
    Fetal Diagn Ther 2011;29:148-54 pdf
  • Karagiannis G, Ashoor G, Maiz N, Jawdat F, Nicolaides KH.
    Maternal thyroid function at eleven to thirteen weeks of gestation and subsequent delivery of small for gestational age neonates.
    Thyroid 2011;21:1127-31
  • Klein K, Rode L, Nicolaides K, Krampl-Bettelheim E, Tabor A; PREDICT Group.
    Vaginal micronized progesterone and the risk of preterm delivery in high-risk twin pregnancies - secondary analysis of a placebo-controlled randomized trial and meta-analysis
    Ultrasound Obstet Gynecol 2011;38:281-7 pdf
  • Lachmann R, Chaoui R, Moratalla J, Picciarelli G, Nicolaides KH.
    Posterior brain in fetuses with open spina bifida at 11 to 13 weeks.
    Prenat Diagn 2011;31:103-6 pdf
  • Lopez MF, Kuppusamy R, Sarracino DA, Prakash A, Athanas M, Krastins B, Rezai T, Sutton JN, Peterman S, Nicolaides K.
    Mass spectrometric discovery and selective reaction monitoring (SRM) of putative protein biomarker candidates in first trimester trisomy 21 maternal serum.
    J Proteome Res 2011 7;10:133-42 pdf
  • Madsen HN, Ball S, Wright D, Tørring N, Petersen OB, Nicolaides KH, Spencer K.
    A reassessment of biochemical marker distributions in trisomy 21-affected and unaffected twin pregnancies in the first trimester.
    Ultrasound Obstet Gynecol 2011;37:38-47 pdf
  • Mastricci AL, Akolekar R, Kuppusamy R, Ahmed M, Nicolaides KH.
    Are Serum Protein Biomarkers Derived from Proteomic Analysis Useful in Screening for Trisomy 21 at 11-13 Weeks?
    Fetal Diagn Ther 2011;30:53-9 pdf
  • Matias A, Maiz N, Montenegro N, Nicolaides K.
    Ductus venosus flow at 11-13 weeks in the prediction of birth weight discordance in monochorionic twins.
    J Perinat Med 2011;39(4):467-70
  • Makgoba M, Nelson SM, Savvidou M, Messow CM, Nicolaides K, Sattar N.
    First-trimester circulating 25-hydroxyvitamin d levels and development of gestational diabetes mellitus.
    Diabetes Care 2011;34:1091-3
  • Nanda S, Savvidou M, Syngelaki A, Akolekar R, Nicolaides KH.
    Prediction of gestational diabetes mellitus by maternal factors and biomarkers at 11 to 13 weeks.
    Prenat Diagn 2011;31:135-41 pdf
  • Nanda S, Akolekar R, Sarquis R, Mosconi AP, Nicolaides KH
    Maternal serum adiponectin at 11-13 weeks of gestation in predicition of macrosomia.
    Prenat Diag 2011;31:479-83 pdf
  • Nanda S, Yu CK, Giurcaneanu L, Akolekar R, Nicolaides KH.
    Maternal serum adiponectin at 11-13 weeks of gestation in preeclampsia.
    Fetal Diagn Ther 2011;29:208-15 pdf
  • Nanda S, Akolekar R, Sodre D, Vaikousi E, Nicolaides KH.
    Maternal serum adiponectin at 11-13 weeks of gestation in pregnancies delivering small for gestation neonates.
    Fetal Diagn Ther 2011;29:274-9 pdf
  • Nicolaides KH.
    A model for a new pyramid of prenatal care based on the 11 to 13 weeks' assessment.
    Prenat Diagn 2011;31:3-6 pdf
  • Nicolaides KH.
    Turning the pyramid of prenatal care.
    Fetal Diagn Ther 2011;29:183-96 pdf
  • Nicolaides KH.
    Screening for fetal aneuploidies at 11 to 13 weeks.
    Prenat Diagn 2011;31:7-15 pdf
  • Nicolaides KH, Chitty LS.
    Fetal therapy: progress made and lessons learnt.
    Prenat Diagn 2011;31:619-20 pdf
  • Papaioannou GK, Syngelaki A, Maiz N, Ross JA, Nicolaides KH.
    Sonographic markers of aneuploidies at 6-10 weeks of gestation.
    Early Hum Dev 2011;87:453-6
  • Papaioannou GI, Syngelaki A, Maiz N, Ross JA, Nicolaides KH.
    Ultrasonographic prediction of early miscarriage.
    Hum Reprod. 2011;26:1685-92
  • Papaioannou GI, Syngelaki A, Maiz N, Ross JA, Nicolaides KH
    Prediction of outcome in dichorionic twin pregnancies at 6-10 weeks' gestation.
    Am J Obstet Gynecol 2011;205:3481-5
  • Pereira S, Ganapathy R, Syngelaki A, Maiz N, Nicolaides KH.
    Contribution of fetal tricuspid regurgitation in first-trimester screening for major cardiac defects.
    Obstet Gynecol 2011;117:1384-91
  • Persico N, Moratalla J, Lombardi C, Zidere V, Allan L, Nicolaides KH.
    Fetal echocardiography at 11-13 weeks by transabdominal high frequency ultrasound.
    Ultrasound Obstet Gynecol 2011;37:296-301 pdf
  • Plasencia W, Akolekar R, Dagklis T, Veduta A, Nicolaides KH.
    Placental volume at 11-13 weeks' gestation in the prediction of birth weight percentile.
    Fetal Diagn Ther 2011;30:23-8 pdf
  • Plasencia W, Garcia R, Pereira S, Akolekar R, Nicolaides KH.
    Criteria for screening and diagnosis of gestational diabetes mellitus in the first trimester of pregnancy.
    Fetal Diagn Ther 2011;30:108-15 pdf
  • Poon LC, Kametas NA, Valencia C, Chelemen T, Nicolaides KH.
    Hypertensive disorders in pregnancy: screening by systolic diastolic and mean arterial pressure at 11-13 weeks.
    Hypertens Pregnancy 2011;30:93-107
  • Poon LC, Karagiannis G, Staboulidou I, Shafiei A, Nicolaides KH.
    Reference range of birth weight with gestation and first-trimester prediction of small-for-gestation neonates.
    Prenat Diagn 2011;31:58-65 pdf
  • Poon LC, Karagiannis G, Stratieva V, Syngelaki A, Nicolaides KH.
    First-trimester prediction of macrosomia.
    Fetal Diagn Ther 2011;29:139-47 pdf
  • Prendergast M, Rafferty G, Davenport M, Persico N, Jani J, Nicolaides K, Greenough A.
    Three-dimensional ultrasound fetal lung volumes and infant respiratory outcome: a prospective observational study.
    BJOG 2011;118:608-14
  • Rode L, Klein K, Nicolaides K, Krampl-Bettelheim E, Tabor A; PREDICT Group.
    Prevention of preterm delivery in twin gestations (PREDICT): A multicentre randomised placebo-controlled trial on the effect of vaginal micronised progesterone.
    Ultrasound Obstet Gynecol 2011;38:272-80 pdf
  • Savvidou MD, Kaihura C, Anderson JM, Nicolaides KH.
    Maternal arterial stiffness in women who subsequently develop pre-eclampsia.
    PLoS One 2011;6:e18703 pdf
  • Savvidou M, Samuel I, Syngelaki A, Poulton M, Nicolaides K.
    First-trimester markers of aneuploidy in women positive for HIV.
    BJOG 2011;118:844-8
  • Savvidou M, Akolekar R, Samaha R, Masconi A, Nicolaides Kh.
    Maternal serum 25-hydroxyvitamin D levels at 11(+0) -13(+6) weeks in pregnant women with diabetes mellitus and in those with macrosomic neonates.
    BJOG 2011;118:951-5
  • Savvidou M, Samuel M, Akolekar R, Poulton M, Nicolaides K.
    First trimester maternal uterine artery Doppler examination in HIV-positive women.
    HIV Med 2011;12:632-6
  • Sifakis S, Akolekar R, Mantas N, Kappou D, Nicolaides KH.
    Maternal serum human placental growth hormone (hPGH) at 11 to 13 weeks of gestation in preeclampsia.
    Hypertens Pregnancy 2011;30:74-82
  • Sifakis S, Akolekar R, Kappou D, Mantas N, Nicolaides KH.
    Maternal serum insulin-like growth factor-binding protein-1 (IGFBP-1) at 11-13 weeks in pre-eclampsia.
    Prenat Diagn 2011;31:196-201 pdf
  • Sifakis S, Akolekar R, Kappou D, Mantas N, Nicolaides KH.
    Maternal serum IGF-I, IGFBP-1 and IGFBP-3 at 11-13 weeks in trisomy 21 and trisomy 18 pregnancies.
    Eur J Obstet Gynecol Reprod Biol 2011;157:166-8
  • Staboulidou I, Pereira S, Cruz JJ, Syngelaki A, Nicolaides KH.
    Prevalence and Outcome of Absence of Ductus Venosus at 11 to 13(+6) Weeks.
    Fetal Diagn Ther 2011;30:35-40 pdf
  • Syngelaki A, Chelemen T, Dagklis T, Allan L, Nicolaides KH.
    Challenges in the diagnosis of fetal non-chromosomal abnormalities at 11-13 weeks.
    Prenat Diagn 2011;31:90-102 pdf
  • NewSyngelaki A, Bredaki FE, Vaikousi E, Maiz N, Nicolaides KH.
    Body Mass Index at 11-13 Weeks' Gestation and Pregnancy Complications.
    Fetal Diagn Ther 2011;30:250-65 pdf
  • Turan OM, Turan S, Berg C, Gembruch U, Nicolaides KH, Harman CR, Baschat AA.
    The duration of persistent abnormal ductus venosus flow and its impact on perinatal outcome in fetal growth restriction.
    Ultrasound Obstet Gynecol 2011 Sep;38(3):295-302 pdf
  • Wright D, Syngelaki A, Staboulidou I, Cruz JJ, Nicolaides KH.
    Screening for trisomies in dichorionic twins by measurement of fetal nuchal translucency thickness according to the mixture model.
    Prenat Diagn 2011;31:16-21 pdf
  • Wright D, Syngelaki A, Birdir C, Bedei I, Nicolaides KH.
    First-Trimester Screening for Trisomy 21 with Adjustment for Biochemical Results of Previous Pregnancies.
    Fetal Diagn Ther 2011;30:194-202 pdf
  • Yu CK, Ertl R, Samaha R, Akolekar R, Nicolaides KH.
    Normal range of maternal serum vitamin D at 11-13 weeks gestation.
    Fetal Diagn Ther 2011;30:94-9 pdf
  • Zvanca M, Gielchinsky Y, Abdeljawad F, Bilardo CM, Nicolaides KH.
    Hepatic artery Doppler in trisomy 21 and euploid fetuses at 11-13 weeks.
    Prenat Diagn 2011;31:22-7 pdf

    • Return to top of page

    ]]>     tag:www.fetalmedicine.com,2010:/fmf//1.237 2010-10-24T23:39:35Z 2010-10-25T23:59:38Z This section contains the randomized trials organized and sponsored by the Fetal Medicine Foundation. For more information on each study, please select from the list below. Prematurity in singletons. Prematurity in twins... FMF This section contains the randomized trials organized and sponsored by the Fetal Medicine Foundation.
    For more information on each study, please select from the list below.

    ]]> Randomize a patient

     

    Prematurity in

    ]]>     Turning the pyramid of prenatal care tag:www.fetalmedicine.com,2010:/fmf//1.233 2010-10-23T12:50:45Z 2012-02-02T15:46:30Z In the 19th century pregnancy care was confined to the time of delivery and reserved for the wealthy. In the beginning of the 20th century the high maternal and infant mortality stimulated the establishment of institutions for provision of antenatal... FMF In the 19th century pregnancy care was confined to the time of delivery and reserved for the wealthy. In the beginning of the 20th century the high maternal and infant mortality stimulated the establishment of institutions for provision of antenatal care.

    In 1929 the Ministry of Health in the UK issued a Memorandum on Antenatal Clinics recommending that women should first be seen at the 16 th week of pregnancy and then 24 and 28 weeks, fortnightly until 36 weeks and then weekly until delivery. No explicit rationale was offered for either the spacing or clinical content of visits yet these guidelines established the pattern of antenatal care that is followed throughout the world until now.old pyramid.jpg

    The high concentration of visits in the third-trimester implies that firstly, most complications occur at this late stage of pregnancy and secondly, most adverse outcomes are unpredictable in the first- or even second-trimester.

    In the last 20 years it has become apparent that more than 90% of all major aneuploidies can be identified at 11-13 weeks' gestation by a combination of maternal characteristics, ultrasound findings and biochemical testing of maternal blood. It is also becoming increasingly apparent that an integrated first hospital visit at 11-13 weeks combining data from maternal characteristics and history with findings of biophysical and biochemical tests can define the patient-specific risk for a wide spectrum of pregnancy complications, including miscarriage and stillbirth, preeclampsia, gestational diabetes mellitus, preterm delivery, fetal growth restriction and macrosomia.

    Early estimation of patient-specific risks for these pregnancy complications would improve pregnancy outcome by shifting antenatal care from a series of routine visits to a more individualized patient and disease-specific approach both in terms of the schedule and content of such visits. A small proportion of women identified as being at high-risk for a variety of pregnancy complications can have close surveillance in specialist clinics. nicolaides pyramid.jpg

    The great majority of women would be identified as being at low-risk for pregnancy complications and in this group the number of medical visits can be substantially reduced.

    Each visit would have a predefined objective and the findings will generate likelihood ratios that can be used to modify the individual patient and disease-specific estimated risk from the initial assessment at 11-13 weeks. In this respect, the 11-13 weeks assessment is likely to be the basis for a new scientific approach to antenatal care that could reduce maternal and perinatal mortality and morbidity.

    This section presents the emerging evidence on the potential value of the 11-13 weeks assessment and sets the basis for a challenge to overturn the 80 years old pyramid of antenatal care.

    In each topic there will be a short lecture summarizing the methodology and results, the pdf files of the relevant scientific publications and a risk calculator to estimate the patient-specific chance for a given condition based on the findings at the 11-13 weeks assessment.

    For comments and suggestions, please email : jaderjcruz@gmail.com

    This new section has been introduced in October 2010 and it has so far been accessed by 42,134 viewers.

    Acknowledgments:

    • Director: Kypros Nicolaides
    • Coordinators: Jader de Jesus Cruz, Ranjit Akolekar

    ]]>  

     

     

    Assessment of risk at 11-13 weeks

     

    • Pyramid of prenatal care
      Publication pdf
    • Screening for aneuploidies
      Publication pdf
    • Risk of miscarriage
      Calculator
      Publication pdf
    • Risk of stillbirth
      Calculator
      Publication pdf
    • Risk of delivering a small for gestation neonate
      Calculator
      Publication pdf
    • Risk of delivering a large for gestation neonate
      Calculator
      Publication pdf
    • Risk of developing preeclampsia
      Calculator
      Publication pdf
    • Risk of developing gestational diabetes mellitus
      Calculator
      Publication pdf
    • Risk of spontaneous delivery before 34 weeks
      Calculator
      Publication pdf

     

    ]]> Bem vindo a Fetal Medicine Foundation tag:www.fetalmedicine.com,2010:/fmf//1.230 2010-10-21T09:17:36Z 2010-10-21T10:40:25Z

    A Fetal Medicine Foundation é uma entidade sem fins lucrativos que tem por objetivo melhorar as condições de saúde de gestantes e seus bebês por meio de pesquisa e treinamento em medicina fetal. A Fundação, com o apoio de um... FMF A Fetal Medicine Foundation é uma entidade sem fins lucrativos que tem por objetivo melhorar as condições de saúde de gestantes e seus bebês por meio de pesquisa e treinamento em medicina fetal.

    A Fundação, com o apoio de um grupo internacional de experts, introduziu um programa educacional tanto para profissionais de saúde quanto para as gestantes (e pais). Introduziu também um séries de certificados de competência em diferentes áreas da medicina fetal.

    Nos últimos 15 anos, a Fetal Medicine Foundation tem desenvolvido e patrocinado pesquisas e treinamento, chegando a um total de mais de R$ 26 milhões, nas seguintes áreas:

    • Diagnóstico precoce de mal formação fetal
    • Screening para defeitos cromossômicos
    • Cirurgia intra-uterina
    • Causas e prevenção de óbito fetal
    • Previsão e prevenção de parto prematuro
    • Pré-eclâmpsia e restrição de crescimento
    • Gestações múltiplas
    • Desenvolvimento de técnicas mais seguras para diagnóstico prenatal

    Para registrar-se na Fetal Medicine Foundation clique aqui.

    Se você já é registrado, clique aqui.

    ]]> Cursos Online

     

    Os cursos são gratuitos e apropriados para profissionais de saúde e pacientes

    Ultra-som das 11-13 semanas

    Avaliação da cérvix

    Acompanhamento antenatal

    Ecocardiografia fetal

    ]]>     2010 tag:www.fetalmedicine.com,2010:/fmf//1.228 2010-08-27T13:49:48Z 2011-01-31T18:41:54Z Akolekar R, Cruz JJ, Foidart JM, Munaut C, Nicolaides KH. Maternal plasma soluble fms-like tyrosine kinase-1 and free vascular endothelial growth factor at 11 to 13 weeks of gestation in preeclampsia. Prenat Diagn 2010;30:191-7 pdf Akolekar R, Farkas DH,... FMF
  • Akolekar R, Cruz JJ, Foidart JM, Munaut C, Nicolaides KH.
    Maternal plasma soluble fms-like tyrosine kinase-1 and free vascular endothelial growth factor at 11 to 13 weeks of gestation in preeclampsia.
    Prenat Diagn 2010;30:191-7 pdf
  • Akolekar R, Farkas DH, Vanagtmael AL, Bombard AT, Nicolaides KH..
    Fetal sex determination using circulating cell-free fetal DNA (ccffDNA) at 11 to 13 weeks of gestation.
    Prenat Diagn 2010;30:918-923 pdf
  • Akolekar R, Pérez Penco JM, Skyfta E, Rodríguez Calvo J, Nicolaides KH.
    Maternal serum placental protein 13 at eleven to thirteen weeks in chromosomally abnormal pregnancies.
    Fetal Diagn Ther 2010;27:72-7 pdf
  • Ashoor G, Kametas NA, Akolekar R, Guisado J, Nicolaides KH.
    Maternal thyroid function at 11-13 weeks of gestation.
    Fetal Diagn Ther 2010;27:156-63 pdf
  • Ashoor G, Rotas M, Maiz N, Kametas NA, Nicolaides KH.
    Maternal thyroid function at 11-13 Weeks of gestation in women with hypothyroidism treated by thyroxine.
    Fetal Diagn Ther 2010;28:22-27 pdf
  • Ashoor G, Maiz N, Rotas M, Jawdat F, Nicolaides KH.
    Maternal thyroid function at 11 to 13 weeks of gestation and subsequent fetal death.
    Thyroid 2010;20:989-93
  • Ashoor G, Maiz N, Rotas M, Kametas NA, Nicolaides KH.
    Maternal thyroid function at 11 to 13 weeks of gestation and subsequent development of preeclampsia.
    Prenat Diagn 2010;30:1032-8 pdf
  • Borenstein M, Minekawa R, Zidere V, Nicolaides K, Allan L.
    Aberrant right subclavian artery at 16 to 23 + 6 weeks of gestation: a marker for chromosomal abnormality.
    Ultrasound Obstet Gynecol 2010;36:548-52 pdf
  • Chaoui R, Nicolaides KH.
    From nuchal translucency to intracranial translucency: towards the early detection of spina bifida.
    Ultrasound Obstet Gynecol 2010;35:133-8 pdf
  • Chiu RW, Sun H, Akolekar R, Clouser C, Lee C, McKernan K, Zhou D, Nicolaides KH, Lo YM.
    Maternal plasma DNA analysis with massively parallel sequencing by ligation for noninvasive prenatal diagnosis of Trisomy 21.
    Clin Chem 2010;56:459-63
  • Cruz JJ, Cruz G, Minekawa R, Maiz N, Nicolaides KH.
    Effect of temperature on the measurement of free beta-hCG and PAPP-A concentration.
    Ultrasound Obstet Gynecol 2010;36:141-6 pdf
  • Dagklis T, Defigueiredo D, Staboulidou I, Casagrandi D, Nicolaides KH.
    Isolated single umbilical artery and fetal karyotype.
    Ultrasound Obstet Gynecol 2010;36:291-5 pdf
  • Defigueiredo D, Dagklis T, Zidere V, Allan L, Nicolaides KH.
    Isolated single umbilical artery: need for specialist fetal echocardiography.
    Ultrasound Obstet Gynecol 2010;36:553-5pdf
  • Deprest JA, Flake AW, Gratacos E, Ville Y, Hecher K, Nicolaides K, Johnson MP, Luks FI, Adzick NS, Harrison MR.
    The making of fetal surgery.
    Prenat Diagn 2010;30:653-67 pdf
  • Deprest J, Breysem L, Gratacos E, Nicolaides K, Claus F, Debeer A, Smet MH, Proesmans M, Fayoux P, Storme L.
    Tracheal side effects following fetal endoscopic tracheal occlusion for severe congenital diaphragmatic hernia.
    Pediatr Radiol 2010;40:670-3
  • Foidart JM, Munaut C, Chantraine F, Akolekar R, Nicolaides KH.
    Maternal plasma soluble endoglin at 11-13 weeks' gestation in pre-eclampsia.
    Ultrasound Obstet Gynecol 2010;35:680-7 pdf
  • Kagan K, Staboulidou I, Cruz JJ, Wright D, Nicolaides K.
    Two-stage first-trimester screening for trisomy 21 by ultrasound assessment and biochemical testing.
    Ultrasound Obstet Gynecol 2010;36:542-7 pdf
  • Kagan KO, Staboulidou I, Syngelaki A, Cruz JJ, Nicolaides KH.
    The 11-13-week scan: diagnosis and outcome of holoprosencephaly, exomphalos and megacystis.
    Ultrasound Obstet Gynecol 2010;36:10-4 pdf
  • Khalil A, Akolekar R, Syngelaki A, Penco JM, Nicolaides KH.
    Effect of chorionic villus sampling on uterine artery Doppler.
    Fetal Diagn Ther 2010;28:9-13 pdf
  • Khalil A, Akolekar R, Pandya P, Syngelaki A, Nicolaides K.
    Chorionic villus sampling at 11 to 13 weeks of gestation and hypertensive disorders in pregnancy.
    Obstet Gynecol 2010;116:374-80
  • Lachmann R, Picciarelli G, Moratalla J, Green N, Nicolaides KH.
    Frontomaxillary facial angle in fetuses with spina bifida at 11-13 weeks.
    Ultrasound Obstet Gynecol 2010;36:268-271 pdf
  • Lewi L, Valencia C, Gonzalez E, Deprest J, Nicolaides KH.
    The outcome of twin reversed arterial perfusion sequence diagnosed in the first trimester.
    Am J Obstet Gynecol 2010;203:213
  • Molina FS, Terra R, Carrillo MP, Puertas A, Nicolaides KH.
    What is the most reliable ultrasound parameter to assess fetal head descent?
    Ultrasound Obstet Gynecol 2010;36:493-499 pdf
  • Molina FS, Nicolaides KH.
    Ultrasound in labor and delivery.
    Fetal Diagn Ther 2010;27:61-7 pdf
  • Maiz N, Nicolaides KH.
    Ductus venosus in the first trimester: contribution to screening of chromosomal, cardiac defects and monochorionic twin complications.
    Fetal Diagn Ther 2010;28:65-71 pdf
  • Moratalla J, Pintoffl K, Minekawa R, Lachmann R, Wright D, Nicolaides K.
    Semi-automated system for the measurement of nuchal translucency thickness.
    Ultrasound Obstet Gynecol 2010;36:412-416 pdf
  • Papaioannou GI, Syngelaki A, Poon LC, Ross JA, Nicolaides KH.
    Normal ranges of embryonic length, embryonic heart rate, gestational sac diameter and yolk sac diameter at 6-10 weeks.
    Fetal Diagn Ther 2010;28:207-19 pdf
  • Paramalingam S, Parkinson E, Sellars M, Diaz-Cano S, Nicolaides KH, Davenport M.
    Congenital segmental emphysema: an evolving lesion.
    Eur J Pediatr Surg 2010;20:78-81
  • Persico N, Molina F, Borenstein M, Azumendi G, Nicolaides KH.
    Nasal bone length in euploid fetuses at 16-24 weeks of gestation by three-dimensional ultrasound.
    Ultrasound Obstet Gynecol 2010;36:285-290 pdf
  • Poon LC, Kametas NA, Chelemen T, Leal A, Nicolaides KH.
    Maternal risk factors for hypertensive disorders in pregnancy: a multivariate approach.
    J Hum Hypertens 2010;24:104-10
  • Poon LC, Akolekar R, Lachmann R, Beta J, Nicolaides KH.
    Hypertensive disorders in pregnancy: screening by biophysical and biochemical markers at 11-13 weeks.
    Ultrasound Obstet Gynecol 2010;35:662-70 pdf
  • Poon LC, Stratieva V, Piras S, Piri S, Nicolaides KH.
    Hypertensive disorders in pregnancy: combined screening by uterine artery Doppler, blood pressure and serum PAPP-A at 11-13 weeks.
    Prenat Diagn 2010;30:216-23 pdf
  • Savvidou MD, Anderson JM, Kaihura C, Nicolaides KH.
    Maternal arterial stiffness in pregnancies complicated by gestational and type 2 diabetes mellitus.
    Am J Obstet Gynecol 2010;203:274.1-7
  • Savvidou M, Nelson SM, Makgoba M, Messow CM, Sattar N, Nicolaides K.
    First trimester prediction of gestational diabetes: examining the potential of combining maternal characteristics and laboratory measures.
    Diabetes 2010;59:3017-22
  • Sifakis S, Akolekar R, Kappou D, Mantas N, Nicolaides KH.
    Maternal serum insulin-like growth factor-I at 11-13 weeks in preeclampsia.
    Prenat Diagn. 2010;30:1026-31 pdf
  • Sifakis S, Akolekar R, Syngelaki A, Cruz JJ, Nicolaides KH.
    Maternal serum human placental growth hormone at 11 to 13 weeks in trisomy 21 and trisomy 18 pregnancies.
    Prenat Diagn 2010;30:212-5 pdf
  • Sifakis S, Staboulidou I, Maiz N, Velissariou V, Nicolaides KH.
    Outcome of pregnancies with trisomy 2 cells in chorionic villi.
    Prenat Diagn 2010;30:329-32 pdf
  • Sonek J, Nicolaides K.
    Additional first-trimester ultrasound markers.
    Clin Lab Med 2010;30:573-92
  • Spencer K, Staboulidou I, Nicolaides KH.
    First trimester aneuploidy screening in the presence of a vanishing twin: implications for maternal serum markers.
    Prenat Diagn 2010;30:235-40 pdf
  • Spencer K, Spencer CE, Stamatopoulou A, Staboulidou I, Nicolaides KH.
    Early vaginal bleeding has no impact on markers used in first trimester aneuploidy screening.
    Prenat Diagn 2010;30:547-50 pdf
  • Tong YK, Chiu RW, Akolekar R, Leung TY, Lau TK, Nicolaides KH, Lo YM.
    Epigenetic-genetic chromosome dosage approach for fetal trisomy 21 detection using an autosomal genetic reference marker.
    PLoS One 2010 20;5:15244
  • Tsui NB, Akolekar R, Chiu RW, Chow KC, Leung TY, Lau TK, Nicolaides KH, Lo YM.
    Synergy of Total PLAC4 RNA concentration and measurement of the RNA single-nucleotide polymorphism allelic ratio for the noninvasive prenatal detection of Trisomy 21.
    Clin Chem 2010;56:73-81
  • Tsui DW, Lam YM, Lee WS, Leung TY, Lau TK, Lau ET, Tang MH, Akolekar R, Nicolaides KH, Chiu RW, Lo YM, Chim SS.
    Systematic identification of placental epigenetic signatures for the noninvasive prenatal detection of Edwards syndrome.
    PLoS One 2010 30;5:15069
  • Von Kaisenberg CS, Wilting J, Dörk T, Nicolaides KH, Meinhold-Heerlein I, Hillemanns P, Brand-Saberi B.
    Lymphatic capillary hypoplasia in the skin of fetuses with increased nuchal translucency and Turner's syndrome: comparison with trisomies and controls.
    Mol Hum Reprod 2010;16:778-89
  • Wright D, Spencer K, Kagan K, Tørring N, Petersen O, Christou A, Kallikas J, Nicolaides K.
    First-trimester combined screening for trisomy 21 at 8-13 weeks.
    Ultrasound Obstet Gynecol 2010;36:404-11 pdf
  • Yang X, Chen M, Wang HF, Leung TY, Borenstein M, Nicolaides K, Sahota DS, Lau TK.
    Learning curve in measurement of fetal frontomaxillary facial angle at 11-13 weeks of gestation.
    Ultrasound Obstet Gynecol 2010;35:530-4 pdf

    • Return to top of page

    ]]>     Bem vindos a Fetal Medicine Foundation tag:www.fetalmedicine.com,2010:/fmf//1.227 2010-08-27T13:25:50Z 2011-09-12T23:06:30Z A Fetal Medicine Foundation é uma entidade sem fins lucrativos que tem por objetivo melhorar as condições de saúde das grávidas e seus bebés por meio de formação e investigação em medicina fetal. A Fundação, com o apoio de um... FMF A Fetal Medicine Foundation é uma entidade sem fins lucrativos que tem por objetivo melhorar as condições de saúde das grávidas e seus bebés por meio de formação e investigação em medicina fetal.
    A Fundação, com o apoio de um grupo internacional de experts, introduziu um programa educacional tanto para profissionais de saúde quanto para as grávidas (e pais). Introduziu também um séries de certificados de competência em diferentes áreas da medicina fetal.
    Nos últimos 15 anos, a Fetal Medicine Foundation tem desenvolvido e patrocinado investigação e ensino, chegando a um total de mais de R$ 26 milhões, nas seguintes áreas:
    • Diagnóstico precoce de malformações fetais
    • Rastreio de aneuploidias
    • Cirurgia intra-uterina
    • Causas e prevenção de morte fetal
    • Rastreio e prevenção de parto prematuro
    • Pré-eclâmpsia e restrição de crescimento
    • Gestações múltiplas
    • Desenvolvimento de técnicas mais seguras para diagnóstico prenatal

    Para registar-se na Fetal Medicine Foundation clique aqui.
    Se já está registado, clique aqui.

    ]]>  

     

    Novidades no site da Fundação

     

    • Videos demonstrando malformações fetais
    • Palestras em diferentes topicos de medicina fetal

     

     

    Online education

     

    Os cursos são gratuitos e apropriados para profissionais de saúde e pacientes

    ]]>     Lectures tag:www.fetalmedicine.com,2010:/fmf//1.224 2010-08-26T18:15:24Z 2012-02-02T15:49:39Z This section contains lectures on different aspects of fetal medicine by leading international experts. The lectures are free of charge and they are appropriate for both fetal medicine experts and any health care professional who wants to be updated on... FMF This section contains lectures on different aspects of fetal medicine by leading international experts.

    The lectures are free of charge and they are appropriate for both fetal medicine experts and any health care professional who wants to be updated on developments in the field.

    This new section of lectures in fetal medicine has been introduced in September 2010 and it has so far been accessed by 53,061 viewers.

    For comments and suggestions, please email : jaderjcruz@gmail.com

    Acknowledgments:

    • Director: Kypros Nicolaides
    • Coordinator: Jader de Jesus Cruz
    ]]>  

    Lectures

     

    ]]>     Videos of fetal defects tag:www.fetalmedicine.com,2010:/fmf//1.222 2010-02-07T20:19:01Z 2012-02-02T15:51:32Z This section contains 267 videos illustrating fetal defects and we are constantly adding more. In order to view the videos you need to select the system (e.g. Brain) and then the specific condition (e.g. Holoprosencephaly). If you want to leave... FMF This section contains 267 videos illustrating fetal defects and we are constantly adding more.

    In order to view the videos you need to select the system (e.g. Brain) and then the specific condition (e.g. Holoprosencephaly).

    If you want to leave any comments or view comments from other users you can use the links at the bottom right of each page.

    We would be grateful to receive videos of interesting cases and your contribution will be acknowledged. Please save your video in any format and forward to jaderjcruz@gmail.com.

    This section on videos of fetal defects has been introduced in February 2010 and has so far had 458,244 views.

    The videos added since August 2011 are indicated as New


    If you want to view the videos please click here.

    Acknowledgments:

    • Director: Kypros Nicolaides
    • Co-ordinator: Jader Cruz
    • Videos: Jader Cruz, Yuval Gielchinsky, Nicola Persico
    ]]>     2009 tag:www.fetalmedicine.com,2010:/fmf//1.220 2010-01-23T15:56:21Z 2011-01-31T16:07:44Z Akbar SA, Khawaja NP, Brown PR, Tayyeb R, Bamfo J, Nicolaides KH. Angiotensin II type 1 and 2 receptors gene polymorphisms in pre-eclampsia and normal pregnancy in three different populations. Acta Obstet Gynecol Scand 2009;88:606-11 Akolekar R, Casagrandi D,... FMF
  • Akbar SA, Khawaja NP, Brown PR, Tayyeb R, Bamfo J, Nicolaides KH.
    Angiotensin II type 1 and 2 receptors gene polymorphisms in pre-eclampsia and normal pregnancy in three different populations.
    Acta Obstet Gynecol Scand 2009;88:606-11
  • Akolekar R, Casagrandi D, Livanos P, Tetteh A, Nicolaides KH.
    Maternal plasma pentraxin 3 at 11 to 13 weeks of gestation in hypertensive disorders of pregnancy.
    Prenat Diagn 2009;29:934-8 pdf
  • Akolekar R, Casagrandi D, Skyfta E, Ahmed AA, Nicolaides KH.
    Maternal serum angiopoietin-2 at 11 to 13 weeks of gestation in hypertensive disorders of pregnancy.
    Prenat Diagn 2009;29:847-51 pdf
  • Akolekar R, Minekawa R, Veduta A, Romero XC, Nicolaides KH.
    Maternal plasma inhibin A at 11-13 weeks of gestation in hypertensive disorders of pregnancy.
    Prenat Diagn 2009;29:753-60 pdf
  • Akolekar R, Syngelaki A, Beta J, Kocylowski R, Nicolaides KH.
    Maternal serum placental protein 13 at 11-13 weeks of gestation in preeclampsia.
    Prenat Diagn 2009;29:1103-8 pdf
  • Akolekar R, Etchegaray A, Zhou Y, Maiz N, Nicolaides KH.
    Maternal serum activin at 11-13 weeks of gestation in hypertensive disorders of pregnancy.
    Fetal Diagn Ther 2009;25:320-7 pdf
  • Anderson JM, Savvidou MD, Kaihura C, McEniery CM, Nicolaides KH.
    Maternal arterial stiffness in pregnancies affected by Type 1 diabetes mellitus.
    Diabet Med 2009;26:1135-40
  • Benavides-Serralde A, Hernández-Andrade E, Fernández-Delgado J, Plasencia W, Scheier M, Crispi F, Figueras F, Nicolaides KH, Gratacós E.
    Three-dimensional sonographic calculation of the volume of intracranial structures in growth-restricted and appropriate-for-gestational age fetuses.
    Ultrasound Obstet Gynecol 2009;33:530-7 pdf
  • Chaoui R, Benoit B, Mitkowska-Wozniak H, Heling KS, Nicolaides KH.
    Assessment of intracranial translucency (IT) in the detection of spina bifida at the 11-13-week scan.
    Ultrasound Obstet Gynecol 2009;34:249-52 pdf
  • Cowans NJ, Stamatopoulou A, Maiz N, Spencer K, Nicolaides KH.
    The impact of fetal gender on first trimester nuchal translucency and maternal serum free beta-hCG and PAPP-A MoM in normal and trisomy 21 pregnancies.
    Prenat Diagn 2009;29:578-81 pdf
  • Deprest JA, Flemmer AW, Gratacos E, Nicolaides K.
    Antenatal prediction of lung volume and in-utero treatment by fetal endoscopic tracheal occlusion in severe isolated congenital diaphragmatic hernia.
    Semin Fetal Neonatal Med 2009;14:8-13
  • Deprest JA, Hyett JA, Flake AW, Nicolaides K, Gratacos E.
    Current controversies in prenatal diagnosis 4: Should fetal surgery be done in all cases of severe diaphragmatic hernia?
    Prenat Diagn 2009;29:15-19 pdf
  • Deprest JA, Gratacos E, Nicolaides K, Done E, Van Mieghem T, Gucciardo L, Claus F, Debeer A, Allegaert K, Reiss I, Tibboel D.
    Changing perspectives on the perinatal management of isolated congenital diaphragmatic hernia in Europe.
    Clin Perinatol 2009;36:329-47
  • Hernandez-Andrade E, Crispi F, Benavides-Serralde JA, Plasencia W, Diesel HF, Eixarch E, Acosta-Rojas R, Figueras F, Nicolaides K, Gratacós E.
    Contribution of the myocardial performance index and aortic isthmus blood flow index to predicting mortality in preterm growth-restricted fetuses.
    Ultrasound Obstet Gynecol 2009;34:430-6 pdf
  • Jani JC, Benachi A, Nicolaides KH, Allegaert K, Gratacós E, Mazkereth R, Matis J, Tibboel D, Van Heijst A, Storme L, Rousseau V, Greenough A, Deprest JA; the Antenatal CDH Registry group.
    Prenatal prediction of neonatal morbidity in survivors with congenital diaphragmatic hernia: a multicenter study.
    Ultrasound Obstet Gynecol 2009;33:64-9 pdf
  • Jani JC, Nicolaides KH, Gratacós E, Valencia CM, Doné E, Martinez JM, Gucciardo L, Cruz R, Deprest JA.
    Severe diaphragmatic hernia treated by fetal endoscopic tracheal occlusion.
    Ultrasound Obstet Gynecol 2009;34:304-10 pdf
  • Kagan KO, Valencia C, Livanos P, Wright D, Nicolaides KH.
    Tricuspid regurgitation in screening for trisomies 21, 18 and 13 and Turner syndrome at 11 + 0 to 13 + 6 weeks of gestation.
    Ultrasound Obstet Gynecol 2009;33:18-22 pdf
  • Kagan KO, Cicero S, Staboulidou I, Wright D, Nicolaides KH.
    Fetal nasal bone in screening for trisomies 21, 18 and 13 and Turner syndrome at 11-13 weeks of gestation.
    Ultrasound Obstet Gynecol 2009;33:259-64 pdf
  • Kagan KO, Etchegaray A, Zhou Y, Wright D, Nicolaides KH.
    Prospective validation of first-trimester combined screening for trisomy 21.
    Ultrasound Obstet Gynecol 2009;34:14-8 pdf
  • Kagan KO, Wright D, Etchegaray A, Zhou Y, Nicolaides KH.
    Effect of deviation of nuchal translucency measurements on the performance of screening for trisomy 21.
    Ultrasound Obstet Gynecol 2009;33:657-64 pdf
  • Kaihura C, Savvidou MD, Anderson JM, McEniery CM, Nicolaides KH.
    Maternal arterial stiffness in pregnancies affected by pre-eclampsia.
    Am J Physiol Heart Circ Physiol 2009;297:759-64
  • Konstantinidou AE, Kaminopetros P, Sifakis S, Fokaefs T, Gougoudi E, Prezerakou M, Kikidi K, Patsouris E, Nicolaides KH.
    Intrauterine laser photocoagulation for congenital lung malformations: late histopathological effects of a novel therapeutic intervention.
    Histopathology 2009;54:904-7
  • Leal AM, Poon LC, Frisova V, Veduta A, Nicolaides KH.
    First-trimester maternal serum tumor necrosis factor receptor-1 and pre-eclampsia.
    Ultrasound Obstet Gynecol 2009;33:135-141 pdf
  • Maiz N, Valencia C, Kagan KO, Wright D, Nicolaides KH.
    Ductus venosus Doppler in screening for trisomies 21, 18 and 13 and Turner syndrome at 11-13 weeks of gestation.
    Ultrasound Obstet Gynecol 2009;33:512-7 pdf
  • Maiz N, Staboulidou I, Leal AM, Minekawa R, Nicolaides KH.
    Ductus venosus Doppler at 11 to 13 weeks of gestation in the prediction of outcome in twin pregnancies.
    Obstet Gynecol 2009;113:860-5
  • Poon LC, Maiz N, Valencia C, Plasencia W, Nicolaides KH.
    First-trimester maternal serum pregnancy-associated plasma protein-A and pre-eclampsia.
    Ultrasound Obstet Gynecol 2009;33:23-33 pdf
  • Poon LC, Kametas NA, Maiz N, Akolekar R, Nicolaides KH.
    First-trimester prediction of hypertensive disorders in pregnancy.
    Hypertension 2009;53:812-8
  • Poon LC, Nekrasova E, Anastassopoulos P, Livanos P, Nicolaides KH.
    First-trimester maternal serum matrix metalloproteinase-9 (MMP-9) and adverse pregnancy outcome.
    Prenat Diagn 2009;29:553-9 pdf
  • Poon LC, Chelemen T, Minekawa R, Frisova V, Nicolaides KH.
    Maternal serum ADAM12 (A disintegrin and metalloprotease) in chromosomally abnormal pregnancy at 11-13 weeks.
    Am J Obstet Gynecol 2009;200:508.1-6.
  • Poon LC, Staboulidou I, Maiz N, Plasencia W, Nicolaides KH.
    Hypertensive disorders in pregnancy: screening by uterine artery Doppler at 11-13 weeks.
    Ultrasound Obstet Gynecol 2009;34:142-8 pdf
  • Poon LC, Karagiannis G, Leal A, Romero XC, Nicolaides KH.
    Hypertensive disorders in pregnancy: screening by uterine artery Doppler imaging and blood pressure at 11-13 weeks.
    Ultrasound Obstet Gynecol 2009;34:497-502 pdf
  • Savvidou M, Akolekar R, Zaragoza E, Poon L, Nicolaides K.
    First trimester urinary placental growth factor and development of pre-eclampsia.
    BJOG 2009;116:643-7
  • Sifakis S, Zaravinos A, Maiz N, Spandidos DA, Nicolaides KH.
    First-trimester maternal plasma cell-free fetal DNA and preeclampsia.
    Am J Obstet Gynecol 2009;201:472.1-7
  • Sinha CK, Islam S, Patel S, Nicolaides K, Greenough A, Davenport M.
    Congenital diaphragmatic hernia: prognostic indices in the fetal endoluminal tracheal occlusion era.
    J Pediatr Surg 2009;44:312-6
  • Spencer K, Staboulidou I, Cruz JJ, Karagiannis G, Nicolaides KH.
    Maternal serum screening marker levels in women with a previous aneuploidy pregnancy.
    Prenat Diagn 2009;29:1242-3 pdf
  • Staboulidou I, Galindo A, Maiz N, Karagiannis G, Nicolaides KH.
    First-trimester uterine artery Doppler and serum pregnancy-associated plasma protein-a in preeclampsia and chromosomal defects.
    Fetal Diagn Ther 2009;25:336-9 pdf
  • Zaragoza E, Akolekar R, Poon LC, Pepes S, Nicolaides KH.
    Maternal serum placental growth factor at 11-13 weeks in chromosomally abnormal pregnancies.
    Ultrasound Obstet Gynecol 2009;33:382-6 pdf

    • Return to top of page

    ]]>     Mauritania tag:www.fetalmedicine.com,2010:/fmf//1.218 2010-01-20T16:00:43Z 2010-01-21T14:07:16Z The Islamic Republic of Mauritania is a sub-Saharan African country with a population of about 3.3 million. It is inhabited by Arab Berbers in the North and Black Africans in the south. Mauritania was a French colony and became an... FMF The Islamic Republic of Mauritania is a sub-Saharan African country with a population of about 3.3 million. It is inhabited by Arab Berbers in the North and Black Africans in the south. Mauritania was a French colony and became an independent country in 1960. The country's political landscape has been marked by a series of coups and democratic transitions, and has attracted international attention for its wide spread practice of slavery.

    Life expectancy is 58 years. Maternal death occurs in about 1 in 100 pregnancies (less than 1 in 10,000 in developed countries) and 1 in 8 babies born alive die by the age of 5 years. There are less than 10 obstetricians for the whole contry and most deliveries are performed by unqualified and often illiterate birth attendants.

    As part of the Look for Life project a team from the Fetal Medicine Foundation visited Nouakchott and Atar in October 2009, to assess the situation concerning pregnancy care and to provide basic training in obstetric ultrasound to a group of midwives and nurses.

    ]]> Mauritania_map.jpg

    Ultrasound training in Mauritania, 2009

    Mauritania_training1.jpg

    Mauritania_training2.jpg

    Dr Catalina De Paco from the Fetal Medicine Foundation training midwives to perform ultrasound scans

    ]]>     Rwanda tag:www.fetalmedicine.com,2010:/fmf//1.217 2010-01-20T14:35:16Z 2010-01-21T14:14:41Z Rwanda, is a country situated on the east central part of Africa with a population of 10.5 million inhabited predominantly by Hutu (80%) and Tutsi ethnic groups. Historically these groups had lived together in harmony but in 1994, following the... FMF Rwanda, is a country situated on the east central part of Africa with a population of 10.5 million inhabited predominantly by Hutu (80%) and Tutsi ethnic groups. Historically these groups had lived together in harmony but in 1994, following the violent death of the president of Rwanda, the country witnessed a violent ethnic massacre in which some 800,000 Tutsis were killed within 3 months. A democratically elected government is now in power.

    Life expectancy is about 50 years. Maternal death occurs in about 1 in 130 pregnancies (less than 1 in 10,000 in developed countries) and 1 in 5 babies born alive die by the age of 5 years.

    As part of the Look for Life project a team from the Fetal Medicine Foundation visited Rwanda in January 2009 to provide training in obstetric ultrasound for a group of obstetricians, midwives and nurses.

    The Foundation has offered scholarships to doctors and midwives from Rwanda to come to London for extensive training in fetal medicine and the first trainee will be arriving in 2010.

    ]]> Rwanda_map.jpg

    Ultrasound training in Kigali, 2009

    Rwanda_training1.JPG

    Rwanda_training2.JPG

    Dr Nerea Maiz and Dr Nicola Persico from the Fetal Medicine Foundation training doctors to perform ultrasound scans

    ]]>     Iraq tag:www.fetalmedicine.com,2010:/fmf//1.216 2010-01-20T12:31:11Z 2010-01-20T19:29:13Z Sky News reported recently on the concerns raised by families in Fallujah, Iraq, where newborn babies appear to be suffering from increased rates of deformities since the 2004 Iraq war. They fear that exposure to chemicals used during the conflict... FMF Sky News reported recently on the concerns raised by families in Fallujah, Iraq, where newborn babies appear to be suffering from increased rates of deformities since the 2004 Iraq war. They fear that exposure to chemicals used during the conflict may have caused this increase but the lack of detailed records makes this claim difficult to assess objectively.

    In the light of this report The Fetal Medicine Foundation has decided to offer scholarships to obstetricians from Fallujah to receive training in London. The doctors will then return to Fallujah to improve the care of pregnant women and ultimately establish a recording system which may enable them to determine the underlying causes for the birth deformities.

    The first doctor is already in London and training in Fetal Medicine.

    For more on this Sky News report and a video click here

    ]]> Iraq_map.jpg

    ]]>     Cervical assessment tag:www.fetalmedicine.com,2009:/fmf//1.207 2009-01-05T23:39:51Z 2010-10-23T13:08:40Z Internet course This internet based course explains the technique of measuring cervical length and the clinical applications of this measurement. The course is compulsory for all sonographers wishing to obtain the FMF Certificate of competence in cervical assessment. The course... FMF Internet course

    This internet based course explains the technique of measuring cervical length and the clinical applications of this measurement.

    The course is compulsory for all sonographers wishing to obtain the FMF Certificate of competence in cervical assessment. The course may also be useful for patients wishing to be better informed on the value of cervical assessment in pregnancy.

    • The course is free of charge
    • It lasts for about 30 minutes
    • If you are a patient and you want to attend the course please click here.
    • If you are a health care practitioner and you want to obtain the FMF Certificate of competence in cervical assessment you need to be registered with the FMF before attending the course:
    • If you already have a FMF ID please login here.
    • If you are not already registered with the FMF then please register here.
    ]]> Internet course on cervical assessment
    Compulsory for FMF Certificate of competence in cervical assessment
    Available in 18 languages.
    Free of charge.
    List of registrants.

    To view the list of health care professionals who have completed the internet based course on cervical assessment please click here.

    ]]>